Novel-Acquired KANK1-ALK Fusion in An Advanced Lung Adenocarcinoma Responds to Alectinib: A Case Report

被引：0
|
作者：
Tang, Q. [1 ]
Xu, S. [1 ]
机构：
[1] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
KANK1-ALK; Alectinib; lung adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.02-01
引用
收藏
页码：S673 / S674
页数：2
相关论文
共 50 条
  • [21] STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
    Su, Cuiyun
    Jiang, Ya
    Jiang, Wei
    Wang, Huilin
    Liu, Sisi
    Shao, Yang
    Zhao, Wenhua
    Ning, Ruiling
    Yu, Qitao
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 12515 - 12519
  • [22] Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion
    Dayyani, Farshid
    Lee, Whayoung
    Houshyar, Roozbeh
    Fontaine, Pauline
    [J]. JCO PRECISION ONCOLOGY, 2023, 7
  • [23] Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
    Lin Zhu
    Jing Qin
    [J]. Discover Oncology, 14
  • [24] Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion
    Xinyi Lin
    Xiaojuan Yang
    Yuan Tan
    Qianqian Duan
    Mei He
    [J]. Investigational New Drugs, 2022, 40 : 1160 - 1163
  • [25] Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
    Zhu, Lin
    Qin, Jing
    [J]. DISCOVER ONCOLOGY, 2023, 14 (01)
  • [26] Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion
    Lin, Xinyi
    Yang, Xiaojuan
    Tan, Yuan
    Duan, Qianqian
    He, Mei
    [J]. INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1160 - 1163
  • [27] Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
    Zhou, Huamiao
    Xu, Binyue
    Xu, Jili
    Zhu, Guomeng
    Guo, Yong
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [28] Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
    Qin, Yanyan
    Li, Fei
    Tan, Yuan
    Duan, Qianqian
    Zhang, Qin
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] AlectinibTransformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib : case report
    [J]. Reactions Weekly, 2016, 1607 (1) : 35 - 35
  • [30] Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
    Rao, Chuangzhou
    Nie, Liangqin
    Wu, Xiaokang
    Miao, Xiaobo
    Chen, Ting
    Chen, Liuxi
    Zhang, Dongqing
    Lin, Quan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
12345